These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 8591576)

  • 21. [Comparative evaluation of prognostic scores in pulmonary embolism ].
    Roca IC; Aursulesei V; Roca M; Datcu MD
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(1):69-74. PubMed ID: 23077875
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A naïve approach for deriving scoring systems to support clinical decision making.
    Barbini P; Cevenini G; Furini S; Barbini E
    J Eval Clin Pract; 2014 Feb; 20(1):1-6. PubMed ID: 23648123
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Calibration inference based on multiple runs of an immunoassay.
    Zeng Q; Davidian M
    Biometrics; 1997 Dec; 53(4):1304-17. PubMed ID: 9423252
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multilevel mixture cure models with random effects.
    Lai X; Yau KK
    Biom J; 2009 Jun; 51(3):456-66. PubMed ID: 19588451
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular risk assessment of pulmonary embolism with the GRACE risk score.
    Paiva LV; Providencia RC; Barra SN; Faustino AC; Botelho AM; Marques AL
    Am J Cardiol; 2013 Feb; 111(3):425-31. PubMed ID: 23168283
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictive model selection for repeated measures random effects models using Bayes factors.
    Weiss RE; Wang Y; Ibrahim JG
    Biometrics; 1997 Jun; 53(2):592-602. PubMed ID: 9192454
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic scoring systems to predict outcome in peritonitis and intra-abdominal sepsis.
    Bosscha K; Reijnders K; Hulstaert PF; Algra A; van der Werken C
    Br J Surg; 1997 Nov; 84(11):1532-4. PubMed ID: 9393271
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pattern-mixture models for multivariate incomplete data with covariates.
    Little RJ; Wang Y
    Biometrics; 1996 Mar; 52(1):98-111. PubMed ID: 8934587
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evidence-based emergency medicine/editorial. The problem with sensitivity and specificity..
    Gallagher EJ
    Ann Emerg Med; 2003 Aug; 42(2):298-303. PubMed ID: 12883522
    [No Abstract]   [Full Text] [Related]  

  • 30. The analysis of placement values for evaluating discriminatory measures.
    Pepe MS; Cai T
    Biometrics; 2004 Jun; 60(2):528-35. PubMed ID: 15180681
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intraperitoneal micro-organisms and the severity of peritonitis.
    Schoeffel U; Jacobs E; Ruf G; Mierswa F; von Specht BU; Farthmann EH
    Eur J Surg; 1995 Jul; 161(7):501-8. PubMed ID: 7488664
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical performance characteristics of a laboratory test. A practical approach in the autoimmune laboratory.
    Bossuyt X
    Autoimmun Rev; 2009 Jun; 8(7):543-8. PubMed ID: 19200856
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic indices in peritonitis.
    Ohmann C; Hau T
    Hepatogastroenterology; 1997; 44(16):937-46. PubMed ID: 9261581
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predicting survival in AIDS patients with respiratory failure. Application of the APACHE II scoring system.
    Chu DY
    Crit Care Clin; 1993 Jan; 9(1):89-105. PubMed ID: 8422618
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the POSSUM scoring system in lung surgery. Physiological and Operative Severity Score for the enUmeration of Mortality and Morbidity.
    Brunelli A; Fianchini A; Xiume F; Gesuita R; Mattei A; Carle F
    Thorac Cardiovasc Surg; 1998 Jun; 46(3):141-6. PubMed ID: 9714489
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detecting potential safety issues in clinical trials by Bayesian screening.
    Gould AL
    Biom J; 2008 Oct; 50(5):837-51. PubMed ID: 18932142
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of current staging systems for advanced hepatocellular carcinoma not amendable to locoregional therapy as inclusion criteria for clinical trials.
    Li X; Dong M; Lin Q; Chen ZH; Ma XK; Xing YF; Wan XB; Wen JY; Wei L; Chen J; Wu XY
    Asia Pac J Clin Oncol; 2013 Mar; 9(1):86-92. PubMed ID: 23279888
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Continuous toxicity monitoring in phase II trials in oncology.
    Ivanova A; Qaqish BF; Schell MJ
    Biometrics; 2005 Jun; 61(2):540-5. PubMed ID: 16011702
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A leptin serum concentration less than 10 ng/ml is a predictive marker of outcome in patients with moderate to severe secondary peritonitis.
    Bracho-Riquelme RL; Reyes-Romero MA; Pescador N; Flores-García AI
    Eur Surg Res; 2008; 41(2):238-44. PubMed ID: 18525209
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nonparametric estimation and testing in a cure model.
    Laska EM; Meisner MJ
    Biometrics; 1992 Dec; 48(4):1223-34. PubMed ID: 1290799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.